Abbott Laboratories has announced its intention to separate its global nutrition business into an independent, publicly traded company. This strategic move is expected to unlock the potential of both Abbott and the new nutrition entity, allowing each to pursue distinct growth and value-creation strategies.
The new nutrition company will emerge as a global leader in the rapidly growing healthy nutrition market, boasting a portfolio of iconic brands, including Similac, PediaSure, Pedialyte, Glucerna, and Ensure. Abbott anticipates that the separation will lead to accelerated sales growth and an expanded margin profile for both companies.
“As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market,” said Robert B. Ford, chairman and chief executive officer of Abbott. “Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition, and it will be better positioned as an independent company to more effectively direct its strategic resources across its priorities.”
Abbott, a leader in the pharmaceutical preparations industry, is known for its innovative healthcare solutions. The company has been actively reshaping its portfolio to focus on high-growth areas, and this latest move is part of that strategy. The separation is expected to be completed by the end of 2027, with Abbott planning to execute a tax-free distribution to its shareholders.
With approximately $8.5 billion in annual sales, the new nutrition company will be well-positioned to capitalize on consumer health and nutrition trends, including metabolic health, prevention, and wellness. The independent entity will have about 16,000 employees and 14 manufacturing sites, enabling it to scale across developed and emerging markets.
The portfolio of the new nutrition company is highly differentiated within its competitive set, supported by evidence-based scientific research and healthcare professional recommendations. This foundation is expected to drive durable organic growth across various channels.
As both Abbott and the new nutrition company pursue their respective strategies, the separation reflects a broader trend in the pharmaceutical preparations sector towards specialization. Companies are increasingly recognizing the benefits of focusing on core competencies to enhance operational efficiency and market responsiveness.
Details were not available in the SEC filing regarding the specific operational changes that will follow this announcement, but the separation is anticipated to provide both entities with the agility needed to adapt to evolving market conditions.
The filing does not say what happens next.